JP5552048B2 - 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド - Google Patents

加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド Download PDF

Info

Publication number
JP5552048B2
JP5552048B2 JP2010513493A JP2010513493A JP5552048B2 JP 5552048 B2 JP5552048 B2 JP 5552048B2 JP 2010513493 A JP2010513493 A JP 2010513493A JP 2010513493 A JP2010513493 A JP 2010513493A JP 5552048 B2 JP5552048 B2 JP 5552048B2
Authority
JP
Japan
Prior art keywords
seq
connexin
amino acid
disclosed
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010513493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530903A5 (enExample
JP2010530903A (ja
Inventor
ローラー，バーベル
ゴーディエ，ロバート
Original Assignee
ムスク ファンデーション フォー リサーチ ディベロップメント
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ムスク ファンデーション フォー リサーチ ディベロップメント filed Critical ムスク ファンデーション フォー リサーチ ディベロップメント
Publication of JP2010530903A publication Critical patent/JP2010530903A/ja
Publication of JP2010530903A5 publication Critical patent/JP2010530903A5/ja
Application granted granted Critical
Publication of JP5552048B2 publication Critical patent/JP5552048B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2010513493A 2007-06-21 2008-06-23 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド Expired - Fee Related JP5552048B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94549307P 2007-06-21 2007-06-21
US60/945,493 2007-06-21
PCT/US2008/067944 WO2008157840A2 (en) 2007-06-21 2008-06-23 Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration

Publications (3)

Publication Number Publication Date
JP2010530903A JP2010530903A (ja) 2010-09-16
JP2010530903A5 JP2010530903A5 (enExample) 2011-08-04
JP5552048B2 true JP5552048B2 (ja) 2014-07-16

Family

ID=40156983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010513493A Expired - Fee Related JP5552048B2 (ja) 2007-06-21 2008-06-23 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド

Country Status (5)

Country Link
US (2) US20110130345A1 (enExample)
EP (1) EP2166845B1 (enExample)
JP (1) JP5552048B2 (enExample)
DK (1) DK2166845T3 (enExample)
WO (1) WO2008157840A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1827480B1 (en) 2004-12-21 2016-11-09 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
MX351881B (es) 2012-03-01 2017-11-01 Firststring Res Inc Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).
WO2013163423A1 (en) * 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
US10981961B2 (en) * 2013-03-11 2021-04-20 University Of Florida Research Foundation, Incorporated Delivery of card protein as therapy for occular inflammation
US11053291B2 (en) 2014-02-19 2021-07-06 University Of Florida Research Foundation, Incorporated Delivery of Nrf2 as therapy for protection against reactive oxygen species
EP4050020A1 (en) 2014-03-11 2022-08-31 University of Florida Research Foundation, Inc. Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
JP7185655B2 (ja) * 2014-08-22 2022-12-07 オークランド ユニサービシーズ リミティド チャネル調節剤
ES2804039A1 (es) * 2019-07-30 2021-02-02 Fund Profesor Novoa Santos Fragmentos peptidicos de cx43 para su uso como agentes senoliticos
US12138293B2 (en) 2020-10-22 2024-11-12 Xequel Bio, Inc. Peptide formulations and ophthalmic uses thereof
CA3252591A1 (en) * 2022-05-13 2023-11-16 Character Biosciences, Inc. THERAPEUTIC LIPID COMPOSITIONS AND TREATMENT METHODS FOR AGE-RELATED MACULAR DEGENERATION
US12667586B2 (en) 2023-03-07 2026-06-30 Glaukos Corporation Treatments for ocular surface disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
US5234809A (en) * 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US7098190B1 (en) * 1999-01-27 2006-08-29 Coda Therapeutics Ltd. Formulations comprising antisense nucleotides to connexins
US7250397B2 (en) * 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
US7364750B2 (en) * 2001-04-30 2008-04-29 The University Of British Columbia Autogene nucleic acids encoding a secretable RNA polymerase
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20050053918A1 (en) * 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
CN1827766B (zh) * 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
US6685971B2 (en) * 2001-06-28 2004-02-03 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
JP2003238441A (ja) * 2002-02-08 2003-08-27 英行 ▲高▼野 血管新生抑制剤
WO2003096981A2 (en) * 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
WO2004073616A2 (en) * 2003-02-14 2004-09-02 Human Matrix Sciences Llc Elastin digest compositions and methods utilizing same
CN1922320B (zh) * 2003-12-03 2013-04-24 科达治疗（新西兰）有限公司 靶向连接蛋白的反义化合物及其使用方法
EP1827480B1 (en) * 2004-12-21 2016-11-09 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
CN101573131B (zh) * 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用

Also Published As

Publication number Publication date
WO2008157840A3 (en) 2009-02-12
EP2166845A2 (en) 2010-03-31
US20110130345A1 (en) 2011-06-02
EP2166845B1 (en) 2015-10-21
WO2008157840A2 (en) 2008-12-24
JP2010530903A (ja) 2010-09-16
EP2166845A4 (en) 2012-08-01
US20140018305A1 (en) 2014-01-16
DK2166845T3 (en) 2016-02-01

Similar Documents

Publication Publication Date Title
JP2010530903A (ja) 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド
US10398140B2 (en) Alpha connexin C-terminal (ACT) peptides and methods of use thereof
JP5602891B2 (ja) 創傷治癒および組織再生を促進するための組成物および方法
US10092624B2 (en) Methods of treating cancers with peptide-based modulators
EP3582754B1 (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
CN101151043B (zh) 促进伤口愈合和组织再生的组合物和方法
EP4232157A1 (en) Peptide formulations and ophthalmic uses thereof
AU2012202117B2 (en) Compositions and methods for promoting wound healing and tissue regeneration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140312

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140523

R150 Certificate of patent or registration of utility model

Ref document number: 5552048

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees